Abstract
Colorectal cancer is among the most frequent causes of cancer death worldwide. An inherited predisposition to cancer of the colon and other organs, Lynch syndrome—also called hereditary non-polyposis colorectal cancer—is probably the most frequent cause of hereditary cancer and is often found in a colon cancer patient and traced through other family members. However, this syndrome is not only characterized by the early onset of colon cancers but also by a predisposition to a constellation of extraintestinal cancers that tend to be misdiagnosed. With new diagnostic technologies, the incidence of familial/inherited versus sporadic cases may appear to increase, due to the recognition of cancers in families that do not fulfill clinical guidelines developed prior to knowledge of the genetic basis of this disease. We now have the ability and the responsibility to detect and prevent this disease, and equally important, to direct patients to specifically targeted treatment. Specialists should be aware of the significance of inherited colon cancer and should become familiar with the molecular diagnostic tests now widely available.
Similar content being viewed by others
References and Recommended Reading
Boland CR: Evolution of the nomenclature for hereditary colorectal cancer. Fam Cancer 2005, 4:211–217.
Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995, 87:1114–1125.
Lynch HT, Krush AJ: Cancer family "G" revisited: 1895–1970. Cancer 1971, 27:1505–1511.
Lynch HT, Shaw MW, Magnuson CW, et al.: Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med 1966, 117:206–212.
Boland CR, Troncale FJ: Familial colonic cancer without antecedent polyposis. Ann Intern Med 1984, 100:700–701.
Lynch HT, Kimberling W, Albano WA, et al.: Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 1985, 56:934–938.
Mecklin JP, Sipponen P, Jarvinen HJ: Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 1986, 29:849–853.
Ponti G, Losi L, Di Gregorio C, et al.: Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005, 103:1018–1025.
Vasen HF, Mecklin JP, Khan PM, Lynch HT: The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424–425.
Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116:1453–1456.
Ionov Y, Peinado MA, Malkhosyan S, et al.: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558–561.
Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816–819.
Aaltonen LA, Peltomaki P, Leach FS, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812–816.
Fishel R: The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 2001, 61:7369–7374.
Bronner CE, Baker SM, Morrison PT, et al.: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368:258–261.
Edelmann W, Yang K, Umar A, et al.: Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997, 91:467–477.
Fishel R, Lescoe MK, Rao MR, et al.: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1994, 77:167.
Kolodner RD, Tytell JD, Schmeits JL, et al.: Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999, 59:5068–5074.
Leach FS, Nicolaides NC, Papadopoulos N, et al.: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993, 75(6):1215–1225.
Peltomaki P, Aaltonen LA, Sistonen P, et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993, 260:810–812.
Wu Y, Berends MJ, Post JG, Mensink RG, et al.: Germlinemutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology 2001, 120:1580–1587.
Hendriks YM, Wagner A, Morreau H, et al.: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127:17–25.
Nakagawa H, Lockman JC, Frankel WL, et al.: Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004, 64(14):4721–4727.
Truninger K, Menigatti M, Luz J, et al.: Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005, 128:1160–1171. This paper highlights the possible role of hPMS2 in causing an attenuated form of Lynch syndrome that may be difficult to diagnose.
Boland CR, Fishel R: Form, function, proteins and basketball. Gastroenterology 2005, 129:751–755.
Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991, 51:3075–3079.
Loeb LA: Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994, 54:5059–5063.
Markowitz S, Wang J, Myeroff L, et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336–1338.
Rampino N, Yamamoto H, Ionov Y, et al.: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967–969.
Souza RF, Appel R, Yin J, et al.: Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 1996, 14:255–257.
Duval A, Hamelin R: Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002, 62:2447–2454.
Lengauer C: Aneuploidy and genetic instability in cancer. Semin Cancer Biol 2005, 15:43–49.
Syngal S, Fox EA, Li C, et al.: Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 1999, 282:247–253.
Lindor NM, Rabe K, Petersen GM, et al.: Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293:1979–1985. This large collaborative study of carefully studied colon cancer families demonstrates that 60% have an identifiable mutation in a DNA MMR gene (ie, have Lynch syndrome) but that 40% do not ("syndrome X").
Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248–5257.
Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al.: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89:1758–1762.
Umar A, Boland CR, Terdiman JP, J et al.: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261–268.
Jass JR: HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004, 3:93–100.
Pinol V, Castells A, Andreu M, et al.: Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005, 293:1986–1994.
Syngal S, Fox EA, Eng C, et al.: Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000, 37:641–645.
Wahlberg SS, Schmeits J, Thomas G, et al.: Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002, 62:3485–3492.
Suraweera N, Duval A, Reperant M, et al.: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002, 123:1804–1811.
Hampel H, Frankel WL, Martin E, et al.: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352:1851–1860. Suggests that the use of immunohistochemistry may be a practical alternative to MSI testing to find Lynch syndrome families.
Lindor NM, Burgart LJ, Leontovich O, et al.: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002, 20:1043–1048.
Bala S, Peltomaki P: CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 2001, 61:6042–6045.
Frazier ML, O’Donnell FT, Kong S, et al.: Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 2001, 61:1269–1271.
Kong S, Amos CI, Luthra R, et al.: Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000, 60:249–252.
Maillet P, Chappuis PO, Vaudan G, et al.: A polymorphism in the ATM gene modulates the penetrance of hereditary nonpolyposis colorectal cancer. Int J Cancer 2000, 88:928–931.
Jones JS, Chi X, Gu X, et al.: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004, 10:5845–5849.
Wu Y, Berends MJ, Sijmons RH, et al.: A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001, 29:137–138.
Lipkin SM, Wang V, Jacoby R, et al.: MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 2000, 24:27–35.
Lu SL, Kawabata M, Imamura T, et al.: HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet 1998, 19:17–18.
Bian Y, Caldes T, Wijnen J, et al.: TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol 2005, 23:3074–3078.
Young J, Barker MA, Simms LA, et al.: Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005, 3:254–263. This provocative report suggests a novel phenotype for familial colorectal cancer, which is distinct from Lynch syndrome.
Jass JR, Whitehall VL, Young J, Leggett BA: Emerging concepts in colorectal neoplasia. Gastroenterology 2002, 123:862–876.
Bandipalliam P, Garber J, Kolodner RD, Syngal S: Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. Gastroenterology 2004, 126:936–937. The authors suggest that hMLH1 germline mutations are associated with Lynch syndrome I, whereas mutations of hMHS2 are associated with Lynch syndrome II.
Lynch HT, Coronel SM, Okimoto R, et al.: A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 2004, 291:718–724.
Wijnen J, van der KH, Vasen H, et al.: MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 1998, 20:326–328.
Casey G, Lindor NM, Papadopoulos N, et al.: Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA 2005, 293:799–809. This report underscores the technical challenges to finding all of the mutations that cause Lynch syndrome.
Whiteside D, McLeod R, Graham G, et al.: A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res 2002, 62:359–362.
Ricciardone MD, Ozcelik T, Cevher B, et al.: Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 1999, 59:290–293.
Bougeard G, Charbonnier F, Moerman A, et al.: Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003, 72:213–216.
Trimbath JD, Petersen GM, Erdman SH, et al.: Cafe-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001, 1:101–105.
Mangold E, Pagenstecher C, Leister M, et al.: A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet 2004, 41:567–572.
Lynch HT, Lynch PM, Pester J, Fusaro RM: The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre’s syndrome. Arch Intern Med 1981, 141:607–611.
Entius MM, Keller JJ, Drillenburg P, et al.: Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000, 6:1784–1789.
Jager AC, Bisgaard ML, Myrhoj T, et al.: Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet 1997, 61:129–138.
Lipkin SM, Rozek LS, Rennert G, et al.: The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet 2004, 36:694–699.
Gallinger S, Aronson M, Shayan K, et al.: Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 2004, 126:576–585.
Scheenstra R, Rijcken FE, Koornstra JJ, et al.: Rapidly progressive adenomatous polyposis in a patient with germline mutations in both the APC and MLH1 genes: the worst of two worlds. Gut 2003, 52:898–899.
Herman JG, Umar A, Polyak K, et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998, 95:6870–6875.
Cunningham JM, Christensen ER, Tester DJ, et al.: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998, 58:3455–3460.
Gryfe R, Kim H, Hsieh ET, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69–77.
Miyakura Y, Sugano K, Konishi F, et al.: Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001, 121:1300–1309.
Samowitz WS, Curtin K, Ma KN, et al.: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001, 10:917–923.
Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP: Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996, 110:682–687.
Ward R, Meagher A, Tomlinson I, et al.: Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001, 48:821–829.
Nagasaka T, Sasamoto H, Notohara K, et al.: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004, 22:4584–4594.
Chang DK, Ricciardiello L, Goel A, et al.: Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 2000, 275:18424–18431.
Giardiello FM, Brensinger JD, Petersen GM: AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001, 121:198–213.
Vasen HF, Nagengast FM, Khan PM: Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995, 345:1183–1184. This brief but important report indicates that some patients with Lynch syndrome who are screened every 3 years with colonoscopy will still develop a (curable) cancer in the interval between examinations.
Carethers JM, Chauhan DP, Fink D, et al.: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117:123–131.
Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003, 106:66–73.
Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247–257. This trial demonstrates that stage III colorectal cancer patients with MSI in the tumor do not derive benefit from adjuvant 5-FU and may be harmed by treatment.
Carethers JM, Smith EJ, Behling CA, et al.: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004, 126:394–401.
Ricciardiello L, Ceccarelli C, Angiolini G, et al.: High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res 2005, 11:4234–4240.
Leichman CG, Lenz HJ, Leichman L, et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997, 15:3223–3229.
Lenz HJ, Leichman CG, Danenberg KD, et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996, 14:176–182.
Tajima A, Hess MT, Cabrera BL, et al.: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004, 127:1678–1684.
Fallik D, Borrini F, Boige V, et al.: Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003, 63:5738–5744.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ricciardiello, L., Boland, C.R. Lynch syndrome (hereditary non-polyposis colorectal cancer): Current concepts and approaches to management. Curr Gastroenterol Rep 7, 412–420 (2005). https://doi.org/10.1007/s11894-005-0012-2
Issue Date:
DOI: https://doi.org/10.1007/s11894-005-0012-2